Last updated on March 2018

Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Patients With Traumatic Brain Injury


Brief description of study

Eligible participants for this study must have a diagnosis of neurobehavioral disinhibition including aggression, agitation, and irritability that persists after brain injury.

This is a multicenter, randomized, placebo-controlled study, consisting of up to 12 weeks of treatment.

Clinical Study Identifier: TX201218

Find a site near you

Start Over

Meridien Research - Tampa

5411 Beaumont Center Blvd. #760 Tampa, FL USA
  Connect »